NCT04808154View on ClinicalTrials.gov

A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of SNP-630 in Health Subjects.

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 22, 2021

Primary Completion Date

August 31, 2021

Study Completion Date

August 31, 2021

Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
DRUG

SNP-630

Subjects will receive one single dose of SNP-630 at Day 1. Blood and urine samples will be obtained to determine the PK of orally administered SNP-630.

Trial Locations (1)

114

Tri-Service General Hospital, Taipei

All Listed Sponsors
lead

Sinew Pharma Inc.

INDUSTRY

NCT04808154 - A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of SNP-630 in Health Subjects. | Biotech Hunter | Biotech Hunter